ARDX Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -55.52% compared to Ardelyx's net margin of -49.65%. Ardelyx's return on equity of -34.68% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Ardelyx has a consensus price target of $10.80, signalling upside risk potential of 172.04%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 49.2%. Given that Ardelyx has higher upside potential than NovaBay Pharmaceuticals, analysts believe Ardelyx is more attractive than NovaBay Pharmaceuticals.

Ardelyx has a beta of 0.762, which suggesting that the stock is 23.846% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $74.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Ardelyx's net income of -$41.1M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Ardelyx's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 2.60x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Nanoviricides has a net margin of -55.52% compared to Ardelyx's net margin of --. Ardelyx's return on equity of -34.68% beat Nanoviricides's return on equity of --.

Ardelyx has a consensus price target of $10.80, signalling upside risk potential of 172.04%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 263.13%. Given that Nanoviricides has higher upside potential than Ardelyx, analysts believe Nanoviricides is more attractive than Ardelyx.

Ardelyx has a beta of 0.762, which suggesting that the stock is 23.846% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $74.1M, which are larger than Nanoviricides quarterly revenues of --. Ardelyx's net income of -$41.1M is lower than Nanoviricides's net income of -$2.2M. Notably, Ardelyx's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 2.60x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -55.52% compared to Ardelyx's net margin of --. Ardelyx's return on equity of -34.68% beat Oragenics's return on equity of --.

Ardelyx has a consensus price target of $10.80, signalling upside risk potential of 172.04%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 420.83%. Given that Oragenics has higher upside potential than Ardelyx, analysts believe Oragenics is more attractive than Ardelyx.

Ardelyx has a beta of 0.762, which suggesting that the stock is 23.846% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $74.1M, which are larger than Oragenics quarterly revenues of --. Ardelyx's net income of -$41.1M is lower than Oragenics's net income of -$2.2M. Notably, Ardelyx's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 2.60x versus 1.84x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -55.52% compared to Ardelyx's net margin of --. Ardelyx's return on equity of -34.68% beat Theriva Biologics's return on equity of --.

Ardelyx has a consensus price target of $10.80, signalling upside risk potential of 172.04%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1438.46%. Given that Theriva Biologics has higher upside potential than Ardelyx, analysts believe Theriva Biologics is more attractive than Ardelyx.

Ardelyx has a beta of 0.762, which suggesting that the stock is 23.846% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $74.1M, which are larger than Theriva Biologics quarterly revenues of --. Ardelyx's net income of -$41.1M is lower than Theriva Biologics's net income of -$4.3M. Notably, Ardelyx's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 2.60x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.